Andrew Advani

MD, FRCP, PhD, MBChB(Hons), BSc

Scientist, Keenan Research Centre for Biomedical Science

Biography

Dr. Andrew Advani is a Staff Endocrinologist and Associate Professor/Clinician Scientist at the Keenan Research Centre for Biomedical Science, St. Michael’s Hospital and Department of Medicine at University of Toronto. His research program is focused on the discovery and development of new treatments for diabetic kidney disease and related cardiovascular and kidney diseases.

Despite current treatments, people with diabetes continue to be affected by the long-term consequences of the disease. These long-term consequences include kidney disease, eye disease, nerve disease and heart disease. Kidney disease due to diabetes is the most common cause of kidney failure requiring treatment with dialysis or a kidney transplant and people with kidney disease are much more likely to die from heart disease. The Advani Lab is committed to conducting research on the causes of kidney disease in diabetes and on the links between kidney disease and heart disease. Through this research, Dr. Advani aims to develop new and better treatments for diabetes to reduce the burden of the condition on the millions of people affected.

Dr. Advani completed his medical training at the University of Edinburgh (UK) in 1996 and his PhD at Newcastle University (UK) in 2003. He was appointed on Staff at St. Michael’s Hospital in 2008. He is a Fellow of the Royal College of Physicians (UK). He has over 50 publications and has won awards from the British Hypertension Society, Royal College of Physicians (UK), Canadian Diabetes Association and Banting and Best Diabetes Centre. Research in the Advani Lab is supported by the Canadian Institutes of Health Research, Canadian Diabetes Association, Heart and Stroke Foundation of Canada and Kidney Foundation of Canada.

The Advani Lab is always interested in hearing from highly motivated and accomplished individuals interested in post-doctoral fellowships or graduate studentships.

Recent Publications

  1. Alghamdi, TA, Batchu, SN, Hadden, MJ, Yerra, VG, Liu, Y, Bowskill, BB et al.. Histone H3 Serine 10 Phosphorylation Facilitates Endothelial Activation in Diabetic Kidney Disease. Diabetes. 2018; :. doi: 10.2337/db18-0124. PubMed PMID:30213824 .
  2. Hadden, MJ, Advani, A. Histone Deacetylase Inhibitors and Diabetic Kidney Disease. Int J Mol Sci. 2018;19 (9):. doi: 10.3390/ijms19092630. PubMed PMID:30189630 PubMed Central PMC6165182.
  3. Batchu, SN, Thieme, K, Zadeh, FH, Alghamdi, TA, Yerra, VG, Hadden, MJ et al.. The Dipeptidyl Peptidase-4 Substrate CXCL12 has Opposing Cardiac Effects in Young Mice and Aged Diabetic Mice Mediated By Ca2+ Flux and Phosphoinositide 3-Kinase γ. Diabetes. 2018; :. doi: 10.2337/db18-0410. PubMed PMID:30150305 .
  4. Yerra, VG, Advani, A. Histones and heart failure in diabetes. Cell. Mol. Life Sci. 2018; :. doi: 10.1007/s00018-018-2857-1. PubMed PMID:29934664 PubMed Central PMC6063320.
  5. Bugyei-Twum, A, Ford, C, Civitarese, R, Seegobin, J, Advani, SL, Desjardins, JF et al.. Sirtuin 1 activation attenuates cardiac fibrosis in a rodent pressure overload model by modifying Smad2/3 transactivation. Cardiovasc. Res. 2018;114 (12):1629-1641. doi: 10.1093/cvr/cvy131. PubMed PMID:29800064 PubMed Central PMC6148332.
  6. Brijmohan, AS, Batchu, SN, Majumder, S, Alghamdi, TA, Thieme, K, McGaugh, S et al.. HDAC6 Inhibition Promotes Transcription Factor EB Activation and Is Protective in Experimental Kidney Disease. Front Pharmacol. 2018;9 :34. doi: 10.3389/fphar.2018.00034. PubMed PMID:29449811 PubMed Central PMC5799228.
  7. Majumder, S, Thieme, K, Batchu, SN, Alghamdi, TA, Bowskill, BB, Kabir, MG et al.. Shifts in podocyte histone H3K27me3 regulate mouse and human glomerular disease. J. Clin. Invest. 2018;128 (1):483-499. doi: 10.1172/JCI95946. PubMed PMID:29227285 PubMed Central PMC5749498.
  8. Rajasekeran, H, Reich, HN, Hladunewich, MA, Cattran, D, Lovshin, JA, Lytvyn, Y et al.. Dapagliflozin in focal segmental glomerulosclerosis: a combined human-rodent pilot study. Am. J. Physiol. Renal Physiol. 2018;314 (3):F412-F422. doi: 10.1152/ajprenal.00445.2017. PubMed PMID:29141939 PubMed Central PMC5899226.
  9. Mann, JFE, Ørsted, DD, Brown-Frandsen, K, Marso, SP, Poulter, NR, Rasmussen, S et al.. Liraglutide and Renal Outcomes in Type 2 Diabetes. N. Engl. J. Med. 2017;377 (9):839-848. doi: 10.1056/NEJMoa1616011. PubMed PMID:28854085 .
  10. Thieme, K, Majumder, S, Brijmohan, AS, Batchu, SN, Bowskill, BB, Alghamdi, TA et al.. EP4 inhibition attenuates the development of diabetic and non-diabetic experimental kidney disease. Sci Rep. 2017;7 (1):3442. doi: 10.1038/s41598-017-03237-3. PubMed PMID:28611444 PubMed Central PMC5469816.
Search PubMed

Affiliations & Other Activities

  • Staff Endocrinologist/Clinician Scientist, Division of Endocrinology, St. Michael’s Hospital
  • Associate Professor/Clinician Scientist, Department of Medicine, University of Toronto
X